建議您使用以下瀏覽器觀看本網站，
以獲得最佳瀏覽效果。
TheratOcular Biotek, a clinical-stage biotechnology company, is exclusively focusing on development of user-friendly and cost-effective treatments for diseases and conditions of the eye.
View MoreOUR PRODUCTS
TO-O-1001
TO-O-1001 for POAG and OH
A patented new generation Rho kinase (ROCK) inhibitor for treating patients with primary open-angle glaucoma or ocular hypertension.
TO-O-1002
Wet AMD
The first “Eye Drops” formulation ever be brought into wet AMD market for patients’ ease of use and overall therapeutic benefit.
TO-O-1003
TO-O-1003 for Dry eye
The unique dual action pathway (promoting tear secretion and anti-inflammatory response) can effectively reduce the discomfort of dry eye patients.
TO-O-1004
TO-O-1004 for Post-Operative Pain and Inflammation with Cataract Surgery
Aiming to treat the post-operative inflammation and improve the quality of life after surgery.
TO-O-1005
TO-O-1005 for Presbyopia
Aiming to restore accommodation ability of lens for Presbyopia patients.
TO-O-1006
TO-O-1006 for Dry AMD
Special formulation to assist the elimination of drusen, and delay dryAMD progression.
PIPELINE
LASTEST NEWS
TO-O-1001 & TO-O-1002 won the 2023 R&D 100 Award
2023.08.22
MG-O-1002 (TO-O-1002) project won the 2023 Edison Awards™
2023.04
ITRI Special Issue ----
Interview with Dr. Sean Chen, chairman of TheratOcular Biotek
2022.12
New blue ocean for ophthalmology drugs; Taiwanese manufacturers are actively improving innovative technologies
2022.12.09
Old formula New amazing effect, TheratOcular Biotek makes it easy to treat eye diseases - Executive VP Simon Huang Interview
2022.11.24
63th Annual Meeting of Ophthalmology & 15th Asia Pacific Vitreoretinal Society (APVRS) Congress
2022.11.18
Press conference of innovative eye drops
2022.11.08
TO-O-1002 Investigator meeting (IM) in Thailand
2022.09.22
The phase II clinical trial of TO-O-1002 approved by the Central Research Ethics Committee (CREC) in Thailand on 11 Aug 2022.
2022.08.15
The phase I/II clinical trials of TO-O-1001 approved by the Australian Human Research Ethics Committee (HREC) on 4 Aug 2022.
2022.08.09
The company Chair, Dr. Sean Chen, and the SAB Chair, Dr. Lu Da-Wen, get together with all the honorary members of the Company Scientific Advisory Borad (SAB) in a banquet.
2022.08
TheratOcular Team meet up with its RD/BD partner, the ITRI-BEL team, at the 2022 Asia Biotech Exhibition.
2022.07
